All In Biotech

Drug Trial Radar · NCT05812781

A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome

A Phase 2A, Single-Arm Study to Evaluate the Safety and Clinical Activity of VTX2735 in Participants With Cryopyrin-Associated Periodic Syndrome (CAPS)

Last checked: Nov 19, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

7

Actual

Start

Mar 18, 2023

Primary completion

Mar 6, 2024

Study completion Mar 6, 2024

Sponsor

Lead sponsor
Zomagen Biosciences Ltd.Industry
Sponsor type
Industry
First posted
Apr 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Cryopyrin-Associated Period Syndrome (CAPS). Approximately 10 patients will take VTX2735 Dose A or VTX2735 Dose B. The study consists of a screening/washout period of up to 28 weeks, a 2 week treatment period, a treatment withdrawal period of up to 2 weeks, another 2 week treatment period, and a 4 week follow up period. The maximum length of treatment is 4 weeks.

Conditions

  • Cryopyrin Associated Periodic Syndrome

Interventions

  • VTX2735Drug

    Dose A

  • VTX2735Drug

    Dose B

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability of VTX2735Time frame: From the initial administration of VTX2735 through study completion, up to 10 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Local Site # 222

    San Diego, California

  • Local Site # 223

    Columbus, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.